A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy (NCT06015295)

🧪 Interventions in This Study

• 18F-Fluciclovine (Axumin) (DIAGNOSTIC_TEST)
• Pet Scan (DIAGNOSTIC_TEST)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• M D Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Brain Metastases

• Preop fSRS for Resectable Brain Metastases — Tampa, Florida
• Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases — Washington D.C., District of Columbia
• Study Assessing QBS72S For Treating Brain Metastases — Palo Alto, California
• Neurocognitive Decline in Patients With Brain Metastases — Dallas, Texas
• MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases — Durham, North Carolina

Explore by condition: All Brain Metastases clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.